Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine... see more

NDAQ:PMN - Post Discussion

View:
Post by kalman007 on Oct 19, 2021 1:54pm

NASDAQ

I would agree that this company needs the exposure of larger indexes.  Hopefully we shareholders won't get beat up in the process.  At the current share price resulting in an enterprise value of only 80 million is a fraction of what the potential upside could be given the success of PMN310.  It's been too long and it seems that deadlines have come and go over the years.  I for one am growing very impatient with Eugene and would like to see concrete strategies to reward it's loyal stakeholders.
Comment by Thenorth1990 on Oct 19, 2021 2:06pm
Nasdaq move is one of those rare times when this management have kept their promise. Announced in March as a priority and already seeing some progress is encouraging and I hope they stick to their other major commitments as well.
Comment by Mole101 on Oct 19, 2021 3:30pm
I'll have to disagree with the Nasdaq wishful thinking , Just because a company does a reverse split and says it's going to the Nasdaq  it doesn't mean that's going to end there .. I believe consolidation it's happening to make the company more attractive to prospective investors and future pp races .. I owen planet you of shares a d I don't buy it..  
Comment by Thenorth1990 on Oct 19, 2021 4:37pm
I fully agree with you but I see this a sign of more control of Boston group , we will see further dilution with another year of being in Nasdaq , unless we generate enough from serology to fund our other operations and I am not that optimistic about revenue from serolgy . It might generate some revenue but not enough to save us from future pp
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities